Destiny Pharma secure financing for anti-MRSA drug

Destiny Pharma, the company behind the world's first light-activated anti-methicillin-resistant Staphylococcus aureus drug, has announced the development of new applications from its drug portfolio.

The company has recently secured a further L3.8 million ($7.4 million) of investment from existing shareholders to progress the new anti-bacterial products, and is already predicting that the drugs will have a dramatic impact on the treatment of infections. The company's sustained investor support is indicative of the continuing confidence in Destiny and its expanding drug portfolio and testament to the continuing success of a company that has successfully secured over L10.0 million in investments to date, the firm says.

Destiny Pharma says it is an unusual company in the traditionally high-risk pharmaceutical sector and its "outstanding success in all trials to date has had investors flocking in." The new applications for Destiny drugs look set to continue this trend and attract even more attention from the investment community in the coming months, the firm adds.